BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Bitdeer Technologies Group ("Bitdeer†or the "Company†) (NASDAQ: BTDR) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BITDEER (BTDR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email. ...

Core Viewpoint - Bitdeer Technologies Group is under investigation for potential violations of federal securities laws following disappointing financial results and delays in product development [1][2]. Financial Performance - On November 10, 2025, Bitdeer reported an unaudited loss of $1.28 per share for Q3 2025, significantly worse than the expected loss of $0.22 per share [2]. - The company's stock price dropped by $2.63, or 14.90%, closing at $15.02 per share on November 11, 2025, as a result of the negative news [3]. Product Development - Bitdeer disclosed substantial delays in the development of its next-generation Seal 04 ASIC chip, which contradicted earlier positive statements made by the company regarding the chip's progress [2].

JEF INVESTIGATION: Jefferies Financial Group Inc. Securities Fraud Investigation is Pending, Investors Notified to Contact BFA LawDecember 08, 2025 8:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 8, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point Bonita Capital for potential violations of the federal securities laws after SEC probe is revealed.If you in ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [2][4]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [5]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption [6][7]. - The launch faced weak demand as many customers had excess inventory of older devices, which contributed to the poor market reception of Inspire V [7]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [8]. - Following this announcement, Inspire's stock price fell by $42.04 per share, a decline of more than 32%, dropping from $129.95 to $87.91 between August 4 and August 5, 2025 [9].

Company Overview - Klarna provides payment, advertising, and digital retail banking solutions to consumers and merchants [2] Investigation Details - Robbins Geller is investigating potential violations of United States federal securities laws involving Klarna Group plc, focusing on whether Klarna and its top executives made materially false and/or misleading statements or omitted material information regarding the company's business and operations [1][2] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm representing investors in securities fraud and shareholder litigation, ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors [3] - In 2024, Robbins Geller recovered over $2.5 billion for investors in securities-related class action cases, more than the next five law firms combined [3]

Core Points - Rosen Law Firm is reminding purchasers of James Hardie Industries plc common stock about the December 23, 2025 lead plaintiff deadline for a class action lawsuit [1][3] - Investors who purchased stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The lawsuit alleges that James Hardie Industries misled investors regarding the strength of its North America Fiber Cement segment between May 20 and August 18, 2025, despite knowing about distributor destocking [5] - The firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]

Core Viewpoint - Jefferies Financial Group Inc. and its trade finance arm Point Bonita Capital are under investigation for potential violations of federal securities laws following a probe by the SEC related to their exposure to First Brands Group, which filed for bankruptcy in September 2025 [1][4]. Group 1: Company Overview - Jefferies is an investment banking and capital markets firm, while Point Bonita Capital serves as its trade finance arm [2]. - Both firms were closely associated with First Brands Group, an auto parts supplier that declared bankruptcy with $12 billion in debt [2][4]. Group 2: Financial Exposure - On October 8, 2025, Jefferies disclosed that it and Point Bonita had approximately $715 million in exposure to First Brands' receivables, accounting for about 25% of Point Bonita's trade finance portfolio [3]. - Following this announcement, Jefferies' stock price dropped by $4.66 per share, or approximately 8%, from $59.10 on October 7, 2025, to $54.44 on October 8, 2025 [3]. Group 3: SEC Investigation Details - The SEC is investigating whether Jefferies provided adequate information to investors regarding their exposure to the auto business, particularly in light of First Brands' bankruptcy [4]. - The investigation also includes scrutiny of internal controls and potential conflicts of interest within Jefferies and Point Bonita [4][5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [2][4]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [5]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption [6][7]. - The company faced weak demand for Inspire V as many customers had excess inventory of older devices [7]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [8]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 to $87.91 between August 4 and August 5, 2025 [9].

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until January 2, 2026, to request to lead the case in the U.S. District Court for the District of Maryland [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Performance - CarMax reported disappointing financial results for Q2 of fiscal year 2026, with a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [6]. - The net income for Q2 was approximately $95.4 million, down from $132.8 million in the previous year [6]. Group 3: Stock Price Impact - Following the financial results announcement on September 25, 2025, CarMax's stock price fell by $11.45 per share, or about 20%, from $57.05 to $45.60 [7]. - The unexpected departure of CEO Bill Nash on November 6, 2025, and a weak preliminary Q3 outlook led to an additional stock price drop of over 24% [7]. Group 4: Market Context - CarMax had previously promoted strong demand for its vehicles, which was allegedly inflated by a temporary surge in purchases before U.S. tariffs were imposed [4].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until January 26, 2026, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [3]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities [3]. Group 2: Company Performance and Stock Impact - Alexandria Real Estate, a real estate investment trust focused on life science industries, reported lower occupancy rates and slower leasing activity, leading to a real estate impairment charge of $323.9 million, with $206 million related to a property in Long Island City, New York [4][5]. - On October 27, 2025, the company announced disappointing 3Q 2025 results and reduced guidance for the fiscal year, resulting in a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 [6].